Hydroxyurea is a medicine used to treat sickle cell anemia (SCA), a blood disorder that makes red blood cells sickle-shaped and sticky. This study aims to find the best way to dose hydroxyurea for children with SCA. Two methods will be tested: the usual way, which is based on weight, and a new way, which is based on how the body processes the drug (pharmacokinetics). The study will be held at Cincinnati Children's Hospital and other centers in the USA. Participants will have to give blood samples three times after taking hydroxyurea. The study will last for 12 months for each child, and it will help see if the new dosing method improves fetal hemoglobin (HbF) levels, a type of hemoglobin that can reduce SCA symptoms.
- Study Duration: 12 months for each participant
- Blood samples needed after taking medicine
- Enrollment expected to last 24 months
How understandable was the trial content above?
Hard to understand
Easy to understand